CRG Sabine Guth-Gundel

24/10/202512:00MARIE CURIECRGSabine Guth-GundelNovartis Biomedical ResearchTherapeutic potential of allosteric HECT E3 ligase inhibition?Host: Valcárcel Juárez, JuanAbstract:Executive Director, Diseases of Aging and Regenerative medicine (DARe) Novartis Biomedical Research

Sabine currently leads the new in vitro Discovery Home of DARe (Disease of Aging and Regenerative Medicine) at Novartis Biomedical Research in Basel, Switzerland. The team of mainly cell and molecular biologist supports DARe's mission by elucidating the molecular mechanisms underlying the hallmarks of aging, establishing complex in vitro models and screening assays to enable early drug discovery in this field.

Sabine joined Novartis in 2001 as postdoctoral fellow in the rheumatoid arthritis unit, before joining the Bone Research Group of the Muscular Skeletal Disease Area (MSD) as lab head and project leader. During this time, she successfully led teams that discovered first-in-class LMW inhibitors for a new target class (ubiquitin E3 ligases) and BMP type1-receptor kinase inhibitor that are both now undergoing clinical evaluation in different diseases.

In 2013 she became the unit head of the Joint, Bone and Tendon Unit of MSD, with a focus on regenerative osteoarthritis and tendinopathy research in tight collaboration with the GNF in San Diego.

Sabine obtained her PhD from the European Molecular Biology Laboratories (EMBL)/University of Tübingen (Germany) working on alternative splicing regulation. Her early research including her postdoctoral work at Novartis focused on various aspects of RNA biology.